Tafinlar® receives FDA Breakthrough Therapy designation for non-small cell lung cancer with BRAF mutation

GlaxoSmithKline plc announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for Tafinlar® (dabrafenib).

http://www.gsk.com/media/press-releases/2014/tafinlar--receives-fda-breakthrough...

Source: GSK news - January 13, 2014 Category: Pharmaceuticals Source Type: news